{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:57:24Z","timestamp":1781650644715,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug resistance limits effectiveness of chemotherapy in colorectal cancer (CRC). Consequently, finding appropriate strategies for re-sensitizing chemo-resistant cells is crucial. Our present study aimed at taking advantage of chemotherapy and gene therapy by restoring microRNA-145 expression in oxaliplatin resistant CRC cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Bioinformatic analysis of clinical CRC datasets demonstrated significantly reduced miR-145 expression in tumor tissues compared with normal samples. Oxaliplatin-resistant SW-480 cells were generated and transfected with a pCMV-miR-145 expression vector. The MTT assay was used to assess cell viability following miR-145 restoration, oxaliplatin treatment, or their combination. Apoptosis was measured via flow cytometry. Gene expression levels of ABCC1, MDR1, K-RAS, MMP-13, Bcl-2, CASP3, CASP8, and CASP9 were analyzed using qRT-PCR, and ABCC1 protein expression was evaluated by western blotting. Cell migration was assessed using a wound-healing assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Co-treatment with miR-145 and Oxaliplatin significantly reduced cell viability, proliferation, and migration and increased apoptosis compared to the either treatments. Restoring miR-145 expression downregulated reduced the drug-resistance genes ABCC1 and MDR1, and reduced decreased expression of oncogenes including K-RAS and Bcl-2, while increasing expression of apoptosis-related genes (CASP3, CASP8, and CASP9).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>miR-145 restoration via decreasing the drug resistance biomarkers ABBCC1 and MDR1, along with other oncogenes like K-Ras and Bcl2, and increasing apoptosis conductors could sensitize oxaliplatin-resistant cells to chemotherapy. This proposes a novel and clinically translatable strategy to control drug resistance in CRC, finding new ways to increasing chemotherapeutic efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43046-026-00349-8","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T23:02:41Z","timestamp":1779663761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["miR-145 restoration overcomes oxaliplatin resistance via ABCC1 in colorectal cancer"],"prefix":"10.1186","volume":"38","author":[{"given":"Mahsa","family":"Sadeghzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Asadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Baradaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venus","family":"Zafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soghra","family":"Bornehdeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haniye","family":"Mohammad Reza Khani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Mansoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Zarredar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariush","family":"Shanehbandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"349_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. Cancer J Clin. 2020;70:7\u201330.","journal-title":"Cancer J Clin"},{"key":"349_CR2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12943-024-02108-6","volume":"23","author":"Y Chen","year":"2024","unstructured":"Chen Y, Liang J, Chen S, Lin N, Xu S, Miao J, Zhang J, Chen C, Yuan X, Xie Z, Zhu E, Cai M, Wei X, Hou S, Tang H. Discovery of vitexin as a novel VDR agonist that mitigates the transition from chronic intestinal inflammation to colorectal cancer. Mol Cancer. 2024;23:196.","journal-title":"Mol Cancer"},{"key":"349_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13046-024-03132-6","volume":"43","author":"R Xu","year":"2024","unstructured":"Xu R, Du A, Deng X, Du W, Zhang K, Li J, Lu Y, Wei X, Yang Q, Tang H. tsRNA-GlyGCC promotes colorectal cancer progression and 5-FU resistance by regulating SPIB. J Experimental Clin Cancer Research: CR. 2024;43:230.","journal-title":"J Experimental Clin Cancer Research: CR"},{"key":"349_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrc.2016.126","volume":"17","author":"R Dienstmann","year":"2017","unstructured":"Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79\u201392.","journal-title":"Nat Rev Cancer"},{"key":"349_CR5","doi-asserted-by":"crossref","unstructured":"Kamran S, Seyedrezazadeh E, Shanehbandi D, Asadi M, Zafari V, Shekari N, Namvar L, Zarredar H. Combination therapy with KRAS and P38\u03b1 SiRNA suppresses colorectal cancer growth and development in SW480 cell line. J Gastrointest Cancer. 2021;1\u20138.","DOI":"10.1007\/s12029-021-00667-1"},{"key":"349_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/tox.22544","volume":"33","author":"MC Chen","year":"2018","unstructured":"Chen MC, Hsu HH, Chu YY, Cheng SF, Shen CY, Lin YJ, Chen RJ, Viswanadha VP, Lin YM, Huang CY. Lupeol alters ER stress-signaling pathway by downregulating ABCG2 expression to induce Oxaliplatin\u2010resistant LoVo colorectal cancer cell apoptosis. Environ Toxicol. 2018;33:587\u201393.","journal-title":"Environ Toxicol"},{"key":"349_CR7","first-page":"1","volume":"15","author":"DA Goldstein","year":"2016","unstructured":"Goldstein DA, Zeichner SB, Bartnik CM, Neustadter E, Flowers CR. Metastatic colorectal cancer: a systematic review of the value of current therapies. Clin Colorectal Cancer. 2016;15:1\u20136.","journal-title":"Clin Colorectal Cancer"},{"key":"349_CR8","doi-asserted-by":"publisher","first-page":"59714","DOI":"10.18632\/oncotarget.10845","volume":"7","author":"M Gao","year":"2016","unstructured":"Gao M, Miao L, Liu M, Li C, Yu C, Yan H, Yin Y, Wang Y, Qi X, Ren J. miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget. 2016;7:59714.","journal-title":"Oncotarget"},{"key":"349_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1423-0127-20-99","volume":"20","author":"KK To","year":"2013","unstructured":"To KK. MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. J Biomed Sci. 2013;20:1\u201319.","journal-title":"J Biomed Sci"},{"key":"349_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.biochi.2018.01.003","volume":"147","author":"C Xia","year":"2018","unstructured":"Xia C, Yang Y, Kong F, Kong Q, Shan C. MiR-143-3p inhibits the proliferation, cell migration and invasion of human breast cancer cells by modulating the expression of MAPK7. Biochimie. 2018;147:98\u2013104.","journal-title":"Biochimie"},{"key":"349_CR11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.biopha.2018.12.094","volume":"111","author":"N Sadeghiyeh","year":"2019","unstructured":"Sadeghiyeh N, Sehati N, Mansoori B, Mohammadi A, Shanehbandi D, Khaze V, Baradaran B. MicroRNA-145 replacement effect on growth and migration Inhibition in lung cancer cell line. Biomed Pharmacother. 2019;111:460\u20137.","journal-title":"Biomed Pharmacother"},{"key":"349_CR12","doi-asserted-by":"publisher","first-page":"10022","DOI":"10.3390\/ijms241210022","volume":"24","author":"WC Cho","year":"2023","unstructured":"Cho WC, Wong CF, Li KP, Fong AH, Fung KY, Au JS. miR-145 as a potential biomarker and therapeutic target in patients with non-small cell lung cancer. Int J Mol Sci. 2023;24:10022.","journal-title":"Int J Mol Sci"},{"key":"349_CR13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.2174\/2772432817666220520085719","volume":"23","author":"D Shanehbandi","year":"2023","unstructured":"Shanehbandi D, Asadi M, Seyedrezazadeh E, Zafari V, Shekari N, Akbari M, Rahbarnia L, Zarredar H. microRNA-based biomarkers in lung cancer: recent advances and potential applications. Curr Mol Med. 2023;23:648\u201367.","journal-title":"Curr Mol Med"},{"key":"349_CR14","first-page":"170","volume":"2","author":"M Sachdeva","year":"2010","unstructured":"Sachdeva M, Mo Y-Y. miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Translational Res. 2010;2:170.","journal-title":"Am J Translational Res"},{"key":"349_CR15","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1007\/s13277-015-3152-5","volume":"36","author":"R-L Liu","year":"2015","unstructured":"Liu R-L, Dong Y, Deng Y-Z, Wang W-J, Li W-D. Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer. Tumor Biology. 2015;36:5011\u20139.","journal-title":"Tumor Biology"},{"key":"349_CR16","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/jcmm.12358","volume":"18","author":"SY Cui","year":"2014","unstructured":"Cui SY, Wang R, Chen LB. Micro RNA-145: a potent tumour suppressor that regulates multiple cellular pathways. J Cell Mol Med. 2014;18:1913\u201326.","journal-title":"J Cell Mol Med"},{"key":"349_CR17","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.3390\/ijms21072619","volume":"21","author":"D Kazmierczak","year":"2020","unstructured":"Kazmierczak D, Jopek K, Sterzynska K, Ginter-Matuszewska B, Nowicki M, Rucinski M, Januchowski R. The significance of MicroRNAs expression in regulation of extracellular matrix and other drug resistant genes in drug resistant ovarian cancer cell lines. Int J Mol Sci. 2020;21:2619.","journal-title":"Int J Mol Sci"},{"key":"349_CR18","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1515\/hsz-2016-0308","volume":"398","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Wang J. MicroRNAs are important regulators of drug resistance in colorectal cancer. Biol Chem. 2017;398:929\u201338.","journal-title":"Biol Chem"},{"key":"349_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/1574-6968.12247","volume":"348","author":"D Shanehbandi","year":"2013","unstructured":"Shanehbandi D, Saei AA, Zarredar H, Barzegari A. Vibration and glycerol-mediated plasmid DNA transformation for Escherichia coli. FEMS Microbiol Lett. 2013;348:74\u20138.","journal-title":"FEMS Microbiol Lett"},{"key":"349_CR20","first-page":"566","volume":"20","author":"Q Fu","year":"2017","unstructured":"Fu Q, Cheng J, Zhang J, Zhang Y, Chen X, Xie J, Luo S. miR-145 inhibits drug resistance to oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98. Zhonghua Wei Chang Wai Ke Za zhi=. Chin J Gastrointest Surg. 2017;20:566\u201370.","journal-title":"Chin J Gastrointest Surg"},{"key":"349_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.abb.2019.01.005","volume":"663","author":"R Gao","year":"2019","unstructured":"Gao R, Fang C, Xu J, Tan H, Li P, Ma L. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145. Arch Biochem Biophys. 2019;663:183\u201391.","journal-title":"Arch Biochem Biophys"},{"key":"349_CR22","first-page":"15308","volume":"8","author":"F Yang","year":"2015","unstructured":"Yang F, Xie Y-Q, Tang S-Q, Wu X-B, Zhu H-Y. miR-143 regulates proliferation and apoptosis of colorectal cancer cells and exhibits altered expression in colorectal cancer tissue. Int J Clin Exp Med. 2015;8:15308.","journal-title":"Int J Clin Exp Med"},{"key":"349_CR23","first-page":"882","volume":"1","author":"MZ Michael","year":"2003","unstructured":"Michael MZ, O\u2019Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific MicroRNAs in colorectal Neoplasia11Note: Susan M. O\u2019Connor and Nicholas G. van Holst Pellekaan contributed equally to this work. Mol Cancer Res. 2003;1:882\u201391.","journal-title":"Mol Cancer Res"},{"key":"349_CR24","doi-asserted-by":"crossref","unstructured":"Xu X-H, Wu X-B, Wu S-B, Liu H-B, Chen R, Li Y. Identification of MiRNAs differentially expressed in clinical stages of human colorectal carcinoma\u2014An investigation in Guangzhou, China. PLoS ONE 9. 2014;e94060.","DOI":"10.1371\/journal.pone.0094060"},{"key":"349_CR25","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3892\/or.2016.5042","volume":"36","author":"S Li","year":"2016","unstructured":"Li S, Wu X, Xu Y, Wu S, Li Z, Chen R, Huang N, Zhu Z, Xu X. miR-145 suppresses colorectal cancer cell migration and invasion by targeting an ETS-related gene. Oncol Rep. 2016;36:1917\u201326.","journal-title":"Oncol Rep"},{"key":"349_CR26","first-page":"29","volume":"23","author":"Q Liu","year":"2018","unstructured":"Liu Q, Yang W, Luo Y, Hu S, Zhu L. Correlation between miR-21 and miR-145 and the incidence and prognosis of colorectal cancer. JBUON. 2018;23:29\u201335.","journal-title":"JBUON"},{"key":"349_CR27","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.3892\/ol.2017.5741","volume":"13","author":"D Cao","year":"2017","unstructured":"Cao D, Qin S, Mu Y, Zhong M. The role of MRP1 in the multidrug resistance of colorectal cancer. Oncol Lett. 2017;13:2471\u20136.","journal-title":"Oncol Lett"},{"key":"349_CR28","doi-asserted-by":"publisher","first-page":"1297093","DOI":"10.3389\/fgene.2023.1297093","volume":"14","author":"A Ghasemian","year":"2023","unstructured":"Ghasemian A, Omear HA, Mansoori Y, Mansouri P, Deng X, Darbeheshti F, Zarenezhad E, Kohansal M, Pezeshki B, Wang Z, Tang H. Long non-coding RNAs and JAK\/STAT signaling pathway regulation in colorectal cancer development. Front Genet. 2023;14:1297093.","journal-title":"Front Genet"},{"key":"349_CR29","first-page":"3403","volume":"19","author":"J Wang","year":"2019","unstructured":"Wang J, Sun Z, Yan S, Gao F. Effect of miR\u2013145 on gastric cancer cells. Mol Med Rep. 2019;19:3403\u201310.","journal-title":"Mol Med Rep"},{"key":"349_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-015-0372-7","volume":"14","author":"Y Yu","year":"2015","unstructured":"Yu Y, Nangia-Makker P, Farhana L, Rajendra SG, Levi E, Majumdar AP. miR-21 and miR-145 Cooperation in regulation of colon cancer stem cells. Mol Cancer. 2015;14:1\u201311.","journal-title":"Mol Cancer"},{"key":"349_CR31","doi-asserted-by":"publisher","first-page":"52983","DOI":"10.18632\/oncotarget.17677","volume":"8","author":"M Chen","year":"2017","unstructured":"Chen M, Li D, Gong N, Wu H, Su C, Xie C, Xiang H, Lin C, Li X. miR-133b down-regulates ABCC1 and enhances the sensitivity of CRC to anti-tumor drugs. Oncotarget. 2017;8:52983.","journal-title":"Oncotarget"},{"key":"349_CR32","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/carcin\/bgq043","volume":"31","author":"J-L Ku","year":"2010","unstructured":"Ku J-L, Shin Y-K, Kim D-W, Kim K-H, Choi J-S, Hong S-H, Jeon Y-K, Kim S-H, Kim H-S, Park J-H. Establishment and characterization of 13 human colorectal carcinoma cell lines: mutations of genes and expressions of drug-sensitivity genes and cancer stem cell markers. Carcinogenesis. 2010;31:1003\u20139.","journal-title":"Carcinogenesis"},{"key":"349_CR33","first-page":"2401","volume":"6","author":"E Hinoshita","year":"2000","unstructured":"Hinoshita E, Uchiumi T, Taguchi K-i, Kinukawa N, Tsuneyoshi M, Maehara Y, Sugimachi K, Kuwano M. Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res. 2000;6:2401\u20137.","journal-title":"Clin Cancer Res"},{"key":"349_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3109\/03602532.2014.901348","volume":"46","author":"T Kunick\u00e1","year":"2014","unstructured":"Kunick\u00e1 T, Sou\u010dek P. Importance of ABCC1 for cancer therapy and prognosis. Drug Metab Rev. 2014;46:325\u201342.","journal-title":"Drug Metab Rev"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00349-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00349-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00349-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:24:32Z","timestamp":1781648672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00349-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["349"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00349-8","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethical Committee of Tabriz University of Medical Sciences (IR. TBZMED. VCR. REC. 1397. 345). I would like to clarify that in this study, we did not involve any human participants. All research was conducted using established cell lines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to partiticipate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}